Use access key #2 to skip to page content.
$6.52 -0.39 (-5.64%)
10/3/2008 4:00 PM

Halozyme Therapeutics, Inc. (HALO)

CAPS Rating:
**

A biopharmaceutical company dedicated to the development and commercialization of recombinant human enzymes for the drug delivery, palliative care, oncology and infertility markets.

View All Commentary (HALO)

Recs

4

Avatar icemeta2 (32.28) Submitted: 3/16/07 8:18 AM : Outperform Start Price: $8.50 HALO Score: -3.23

Just signed a $600 million deal with Roche, a $100+ million deal with Baxter, and has a drug comimg to market in 6 months, there are only 35 employees, production is jobbed out saving capital exp and mfg problems. The only stock I have that could be 20x in 3 years.

Report this Post Replies: 0 | Reply

Featured Broker Partners